Celltrion Celebrates Brazilian Tender Win For Infliximab

Remsima Win Follows Truxima (Rituximab) And Herzuma (Trastuzumab) Biosimilars

 
• By Dave Wallace

Celltrion’s Remsima infliximab biosimilar has won a Brazilian federal tender as well as several individual state bids, following earlier awards for the Korean firm’s Truxima (rituximab) and Herzuma (trastuzumab) biosimilars.

Brazil flag sky sun
Remsima has become the third Celltrion biosimilar to win a Brazilian tender • Source: Wavebreak Media ltd / Alamy Stock Photo

More from Biosimilars

More from Products